NCT04248712

Antihistamines in Eosinophilic Esophagitis

A Phase II, Randomized, Placebo-controlled Study Evaluating the Efficacy of Antihistamines in the Treatment of Eosinophilic Esophagitis (the ATEE Study)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Researchers are assessing the safety and effectiveness of antihistamines in the treatment of eosinophilic esophagitis.

Detailed description

The purpose of this research is to determine if antihistamines are safe and effective for the treatment of eosinophilic esophagitis. Antihistamines are frequently used for the treatment of gastroesophageal reflux disease and allergic disorders, and we hypothesize they will be effective in the treatment of eosinophilic esophagitis as well. The two antihistamines used in this study are loratadine and famotidine.

Conditions

• Eosinophilic Esophagitis

Interventions

Type	Name	Description
DRUG	Famotidine	40 mg tab twice daily by mouth for 12 week duration
DRUG	Loratadine	10 mg tab once daily by mouth for 12 week duration
DRUG	Placebo	Contains no active ingredient

Timeline

• Start date: 2020-07-10
• Primary completion: 2021-12-31
• Completion: 2021-12-31
• First posted: 2020-01-30
• Last updated: 2022-12-20
• Results posted: 2022-12-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study